MRNA earnings: next report 2026-07-31, real EPS beat/miss history, analyst consensus Hold, P/E -7.13. Updated 2026-07-23.
Moderna (MRNA) Research Hub
Moderna (MRNA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 143.97 USD (+6.16%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.13, market cap 23.26B. This hub links to the full technical, earnings and options research available for MRNA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 143.97 USD (+6.16%) |
| 52-week range | 49.84 USD – 176.66 USD |
| Trend regime | Range |
| 14-day RSI | 69.1 (Bullish) |
| Trailing P/E | -7.13 |
| Market cap | 23.26B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-31 |
Available research for MRNA
Covered Call on MRNA: how it works, illustrative setup around the real 143.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MRNA: how it works, illustrative setup around the real 143.97 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MRNA: how it works, illustrative setup around the real 143.97 USD price, max profit/loss, breakeven and when to use it. Educational.
MRNA technical analysis: range, last 143.97 USD, RSI 69.1, 52w range 49.84 USD–176.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MRNA in?
Moderna (MRNA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MRNA in an uptrend or downtrend?
As of 2026-09-11, MRNA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MRNA's trailing P/E ratio?
MRNA's trailing P/E is -7.13, with a market cap of 23.26B. See the earnings research page for full valuation detail.
When does MRNA next report earnings?
MRNA is next scheduled to report earnings on 2026-07-31, with a consensus EPS estimate of -2 USD.